Rationale and design of a randomized controlled clinical trial of functional electrical stimulation cycling in persons with severe multiple sclerosis  by Pilutti, Lara A. et al.
lable at ScienceDirect
Contemporary Clinical Trials Communications 3 (2016) 147e152Contents lists avaiContemporary Clinical Trials Communications
journal homepage: www.elsevier .com/locate/conctcRationale and design of a randomized controlled clinical trial of
functional electrical stimulation cycling in persons with severe
multiple sclerosis
Lara A. Pilutti*, Robert W. Motl, Thomas A. Edwards, Kenneth R. Wilund
Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, 906 S. Goodwin Ave., Urbana, IL 61801, USAa r t i c l e i n f o
Article history:
Received 28 January 2016
Received in revised form
27 April 2016
Accepted 11 May 2016
Available online 15 May 2016
Keywords:
Multiple sclerosis
Randomized controlled trial
Exercise
Walking
Fitness* Corresponding author. Department of Kinesiolo
University of Illinois at Urbana-Champaign, 213 Free
Urbana, IL 61801, USA.
E-mail address: lpilutti@illinois.edu (L.A. Pilutti).
http://dx.doi.org/10.1016/j.conctc.2016.05.005
2451-8654/© 2016 The Authors. Published by Elseviera b s t r a c t
Background: This randomized controlled trial (RCT) will examine the efﬁcacy of supervised functional
electrical stimulation (FES) cycling on walking performance and physiological function among persons
with multiple sclerosis (MS) with severe mobility disability.
Methods/design: This RCT will recruit 16 persons with MS that require unilateral or bilateral assistance
for ambulation (i.e., Expanded Disability Status Scale (EDSS) score ¼ 6.0e6.5). Participants will be ran-
domized to one of two conditions: supervised FES cycling or passive cycling. The FES cycling condition
will involve mild electrical stimulation that will generate an activation pattern that results in cycling the
leg ergometer. The passive cycling condition will not provide any electrical stimulation, rather the
movement of the pedals will be controlled by the electrical motor. Both conditions will be delivered 3
days/week for the same duration, over 6 months. Primary outcomes will include walking performance
assessed as walking speed, endurance, and agility. Secondary outcomes will include physiological
function assessed as cardiorespiratory ﬁtness, muscular strength, and balance. Assessments will take
place at baseline, mid-point (3-months), and immediately following the intervention (6-months).
Discussion: This study will lay the foundation for the design of a future RCT by: (1) providing effect sizes
that can be included in a power analysis for optimal sample size estimation; and (2) identifying
cardiorespiratory ﬁtness, muscular strength, and balance (i.e., physiological function) as mechanisms for
the beneﬁcial effects of FES cycling on walking performance. This trial will provide important infor-
mation on a novel exercise rehabilitation therapy for managing walking impairment in persons with
severe MS.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiple sclerosis (MS) affects an estimated 1 per 1000 persons
in the United States [1,2]. The disease pathology initially involves
immune-mediated demyelination and transection of axons within
the central nervous system (CNS), and later transitions into a
neurodegenerative process associated with axo-neuronal loss
[3e5]. The extent and location of this damage within the CNS re-
sults in walking dysfunction [6] that can be exacerbated by physi-
ological deconditioning or detraining brought about by physical
inactivity [7,8]. Exercise training is one approach for increasinggy and Community Health,
r Hall, 906 S. Goodwin Ave.,
Inc. This is an open access article uphysical activity, improving physiological function, and restoring
walking performance in persons with MS [7e9].
Exercise training has a variety of beneﬁcial effects for persons
with MS [10e12]; however, the majority of previous research has
been conducted in samples with mild or moderate disability levels
(i.e., Expanded Disability Status Scale (EDSS) scores <6.0) rather
than among those with severe ambulatory impairment [10,13,14].
This is critical considering long-standing arguments that rehabili-
tation, including exercise training, is the only practical means of
preserving and improving functional outcomes in patients with
severeMS [14,15]. The provision of exercise training in persons with
severeMS disability requires specialized trainingmodalities [16,17].
One such approach involves functional electrical stimulation (FES)
cycling [16,17].
FES cycling is an activity-based rehabilitation modality that in-
volves transcutaneous electrical stimulation of leg muscles as annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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effective for improving walking performance and physiological
function (e.g., cardiorespiratory ﬁtness and muscular strength) in
persons with incomplete spinal cord injury (SCI) and stroke
[17e19]. Few studies, however, have examined the potential of FES
cycling in persons with MS. One observational study has docu-
mented beneﬁts of unsupervised FES cycling delivered over 6
months on walking speed and endurance, gait, and muscular
strength in 5 persons with severe MS (mdn EDSS ¼ 6.5) [20]. Two
small (n ¼ 8), uncontrolled studies involving 12e18 sessions of FES
cycling demonstrated improved muscle metabolism [21] and
increased thigh volume [22] in severe MS samples (EDSS> 6.0). FES
cycling is an exercise rehabilitation approach that can be delivered
in the home for potentially managing progressive mobility
disability in severe MS. However, before home-based FES cycling
can be pursued, we require high quality pilot data from a ran-
domized trial with an appropriate control condition that demon-
strates initial efﬁcacy of this intervention.
This study involves a randomized controlled trial (RCT) for
examining the efﬁcacy of 6-months of supervised FES cycling
versus a passive cycling control condition on walking performance
and physiological function among persons with severe MS
disability (i.e., EDSS ¼ 6.0e6.5). This study will lay the foundation
for the design of a future RCT by: (1) providing effect sizes that can
be included in a power analysis for optimal sample size estimation;
and (2) identifying cardiorespiratory ﬁtness, muscular strength,
and balance (i.e., physiological function) as mechanisms for the
beneﬁcial effects of FES cycling on walking performance.
2. Methods
2.1. Study design, overview and hypotheses
The proposed study will take place at the University of Illinois
Urbana-Champaign campus. The studywill involve a parallel group,
assessor-blinded, RCT design for examining the efﬁcacy of super-
vised FES cycling versus a passive cycling condition in patients with
MS that require unilateral or bilateral assistance for ambulation.
The primary outcome of the study will be walking performance
assessed using the Timed 25-Foot Walk (T25FW), the 2-Minute
Walk (2 MW), and the Timed Up-and-Go (TUG) tests. Secondary
outcomes will involve measures of physiological function including
cardiorespiratory ﬁtness measured as peak oxygen consumption
from an incremental exercise test, muscular strength assessed as
peak torque of the knee ﬂexors and extensors on a computerized
dynamometer, and static balance assessed as center of pressure
motion quantiﬁedwith a force platform.Wewill recruit a sample of
16 persons with severe MS (i.e., EDSS score ¼ 6.0e6.5). Participants
who meet the eligibility criteria will be randomly allocated into
either the FES cycling condition or the passive cycling condition.
The FES cycling condition will involve mild electrical stimulation to
the leg muscles that will generate an activation pattern that results
in cycling the leg ergometer. The passive cycling condition will not
provide any electrical stimulation to the leg muscles, rather the
movement of the pedals will be controlled by the electrical motor.
Both conditions will be delivered 3 days per week for the same
duration, over 6 months using RT300 cycles (Restorative Therapies
Inc, Baltimore, MD). Primary and secondary outcomes will be
collected at baseline, 3-months, and 6-months. The effect of the
intervention on primary and secondary outcomes will be examined
using a Condition (FES cycling vs. Passive cycling)  Time (Baseline,
3-months, 6-months) mixed model analysis of variance (ANOVA).
The role of physiological function as a mediator of the effect of FES
cycling on mobility will be examined using bivariate correlation
and multiple linear regression analyses. We hypothesize that therewill be an improvement in walking performance and physiological
function among individuals who receive FES cycling compared to
those who receive passive cycling. We expect FES cycling will have
a positive effect on walking performance through its inﬂuence on
physiological function (i.e., cardiorespiratory ﬁtness, muscular
strength, and balance).
2.2. Participants
We plan to enroll a sample of 16 persons with MS to this trial.
Participants will be recruited through advertisements in local me-
dia outlets. We will further distribute study information to in-
dividuals who have participated in previous research with our
laboratory or who have inquired about previous exercise training
studies, but were disqualiﬁed based on disability status (i.e.,
EDSS 6.0). The study will be described as an opportunity to
participate in one of two leg cycling exercise programs. Participants
will be asked to contact the Clinical Exercise Physiology Laboratory
for information on study participation and screening for inclusion.
The criteria for study inclusion are listed in Table 1. We will include
participants irrespective of disease-modifying or symptomatic
therapies, but will record this information at each testing session to
control for potential covariates in data analysis.
2.3. Sample size
We estimated the sample size for detecting a Condition [2 levels
of between-subjects factor: FES cycling vs. Passive cycling]  Time
[3 levels of within-subjects factor: 0, 3, and 6 months] interaction
using the effect size [d¼ 0.73] from a published observational study
of FES cycling on mobility in advanced MS [20] and assumptions of
a ¼ 0.05, b ¼ 0.20, ICC ¼ 0.50, and ε ¼ 1.0. These parameters were
selected based on the pilot nature of this investigation and the
population that will be targeted. The minimal sample for testing
the interaction should be 14 participants, and we will recruit 16
individuals with severe MS to account for potential attrition
(~10e15%).
2.4. Measures
2.4.1. Disability
A clinically-administered EDSS [23] examination will be con-
ducted to conﬁrm self-reported disability status and to describe the
disability level of the sample. The EDSS will be performed by a
member of the research team who is Neurostatus certiﬁed.
2.4.2. Timed 25-Foot Walk (T25FW)
The T25FWwill be administered as a measure of walking speed,
and will be administered according to standardized instructions
[24]. Participants will be instructed to walk 25 feet as quickly as
possible, but safely. An average of twowalking trials in seconds will
be computed and also converted to walking speed in m/s.
2.4.3. 2-Minute Walk (2MW)
The 2MW test will be administered as a measure of walking
endurance and will be performed according to standardized in-
structions [25]. Participants will be asked to walk as fast and as far
as possible for the duration of 2 min in an accessible corridor that is
free of obstructions. A member of the research team will follow
1e3m behind the participant with ameasuring wheel to record the
total distance traveled inmeters. Based on the target disability level
of the sample, the 2WM was selected as a measure of walking
endurance to ensure that all participants will be able to complete
the test.
Table 1
Inclusion criteria for study participation.
Criteria Description
Age 18e64 years of age
MS diagnosis Conﬁrmed diagnosis of MS based on Poser’s and/or McDonald’s criteria
Disability level EDSS score ¼ 6.0e6.5 (i.e., unilateral or bilateral assistance for ambulation)
Relapse-free No history of a relapse within the past 30 days
Non-exerciser Not currently participating in exercise on 2 or more days per week
Asymptomatic No known cardiovascular, pulmonary, or metabolic disease or major signs or symptoms suggestive of these conditions based on the Physical
Activity Readiness Questionnaire
Pregnancy Not currently pregnant or plans to become pregnant during the study period
Contraindications to FES
cycling
No known contraindications to FES cycling including epilepsy, a pacemaker, an implanted deﬁbrillator, unstable fracture or implanted screws
or pins
Physician approval Physician approval for exercise testing and training
NOTE: EDSS ¼ Expanded Disability Status Scale; FES ¼ functional electrical stimulation; MS ¼ multiple sclerosis.
L.A. Pilutti et al. / Contemporary Clinical Trials Communications 3 (2016) 147e152 1492.4.4. Timed Up-and-Go (TUG)
The TUG test will be administered as a measure of walking
agility [26,27]. Participants will begin the task in a seated position
with their back against the back of the chair. Participants will be
asked to rise from the chair, walk 3 m, turn around, and then walk
back to the chair and return to a seated position. Participants will
complete two trials of the TUG test at a comfortable pace, and the
time taken in seconds for each trial will be recorded.
2.4.5. Cardiorespiratory ﬁtness (CRF)
CRF will be measured as peak oxygen consumption (VO2peak)
using an incremental exercise test on a recumbent stepper (Nustep
T5XR, Nustep Inc, Ann Arbor, MI). Expired gases will be collected
using a two-way non-rebreathable valve and an open-circuit
spirometry system (TrueOne, Parvo Medics, Sandy, UT) for
analyzing expired gases [28,29]. Participants will complete a 1-min
warm-up at 15 W. The initial exercise intensity will be set to 15 W
and will gradually increase by 5 W per minute until the participant
can no longer continue exercising (i.e., volitional fatigue). Partici-
pants will wear a heart rate monitor (Polar Electro Oy, Finland) for
continuous monitoring of heart rate response during exercise.
Participants will be asked to rate their subjective experience of the
exercise intensity using the Borg Rating of Perceived Exertion (RPE)
scale. Heart rate and RPE will be recorded every minute during the
test. VO2peak (ml/kg/min) will be determined as the highest recor-
ded 20-s VO2 value when at least one of the following criteria are
satisﬁed: (1) plateau in VO2 despite increases in work rate; (2)
respiratory exchange ratio 1.10; (3) peak heart rate within 10
beats/minute of age-predicted maximum; or (4) peak rating of
perceived exertion 17. This protocol has been developed and
tested in individuals with severe MS disability (i.e., EDSS 6.0)
[28].
2.4.6. Muscular strength
Bilateral isometric knee extensor and ﬂexor peak torque will be
measured using a Biodex System 3 dynamometer (Shirley, NY) [28].
Participants will be seated on the dynamometer according to the
manufacturer’s recommendations with the hip and knee ﬂexed at
90 and 60, respectively. Participants will be asked to perform
three, 5-s maximal knee extensions and three, 5-s maximal knee
ﬂexions. A 5-s rest period between each contraction attempt will be
provided. Peak torque (Nm) will be determined as the highest
recorded value for each muscle group.
2.4.7. Static balance
Static balance will be based upon assessments of the motion of
the center of pressure (COP) quantiﬁed with a force platform
(Bertec Corporation, Columbus, OH) [29]. Participants will stand
without shoes on the force platform. Participants will not bepermitted to use assistive devices, but will be permitted to wear
ankle-foot orthoses as needed. We will collect two, 30-s trials on
the force platform with a 30-s break between trials. Data collected
from the trials will be quantiﬁed as the amount of postural motion
indexed with sway area (based on a 95% conﬁdence ellipse area)
and velocity of postural sway along the anteroposterior (AP) and
mediolateral (ML) axes [29].
2.5. Intervention
The FES cycling and passive cycling conditions will be delivered
using RT300 cycles (see Fig. 2). The RT300 devices are FDA
approved and consist of an electrically powered motor and multi-
channel FES controlled by a microprocessor and custom software.
Both conditions will be delivered three days per week for the same
duration, over 6months. At each sessionwewill record the distance
traveled, pedaling energy in kcal, power in watts, and resistance in
Nm, as well as heart rate and RPE. Each participant will be provided
a log book for recording the training parameters as well as any
adverse events experienced. Both interventions will be delivered by
members of the research team trained in delivery of FES cycling and
exercise training in persons with MS.
2.5.1. FES cycling condition
Participants in the FES cycling condition will receive electrical
stimulation during the exercise session. All participants will receive
self-adhering surface electrodes (Pals Platinum, Axelgaard
manufacturing CO, Ltd, Fallbrook, CA) that will be placed over three
muscle groups of the lower extremities including the quadriceps,
hamstrings, and gluteal groups. The microprocessor of the RT300
will generate an activation pattern of the leg muscles that results in
a cycling motion. The FES stimulation parameters will be set as
follows: waveform symmetric biphasic, phase duration 250 ms, and
pulse rate 50 pulses per second. These parameters are consistent
with existing FES cycling protocols in MS [20,22]. The intensity and
duration of leg cycling will be prescribed based on guidelines for
aerobic exercise training developed for persons with MS [30] and
from the American College of SportsMedicine (ACSM) [31]. Initially,
the duration of exercise will be 10 min per session throughout the
ﬁrst month and will increase by 10 min each month until the
participant is capable of performing 30 min of exercise. Exercise
durationwill be maintained at 30min for months 4 through 6. Each
sessionwill begin and endwith 5min of passive leg cycling without
electrical stimulation. Participants will be asked to maintain a
cycling cadence of ~40e50 rpm throughout the training sessions.
The intensity of leg muscle stimulation will be adjusted per muscle
group based on the patient’s sensory tolerance with the goal of
maintain pedaling action and target heart rate over the entire
session. Pedaling resistance will be adjusted in order to maintain
Fig. 2. Photograph of the RT300 functional electrical stimulation cycles (Restorative
Therapies Inc, Baltimore, MD).
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2.5.2. Passive cycling condition
Patients in the passive cycling condition will undergo the same
duration and frequency of training as participants in the FES cycling
condition. However, participants will not receive any electrical
stimulation. As a result, the pedaling motion will be generated
entirely by the electric motor of the cycle ergometer. Cycling
cadence will be maintained at ~40e50 rpm. Participants will be
reminded at the training sessions to refrain for actively partici-
pating in leg cycling. Wewill monitor heart rate and RPE during the
training sessions as an indicator of participant effort. The passive
cycling condition will control for attention and social contact
associatedwith delivery of supervised FES cycling, andwill allow us
to understand the effect of FES cycling independent of changes that
might occur in response to passive leg movement by the cycle
ergometer.
2.6. Procedure
The study protocol will be approved by an Institutional Review
Board. Fig. 1 provides a schematic of the study protocol. Interested
participants will contact our laboratory for information on study
participation. Participant screening will be conducted over the
telephone and will involve the completion of a checklist based on
inclusion criteria (see Table 1), the self-reported EDSS [32] and the
Physical Activity Readiness Questionnaire (PAR-Q) [33]. This will
allow for initial identiﬁcation of persons with EDSS scores of
6.0e6.5 (i.e., unilateral or bilateral assistance for ambulation) who
are inactive and asymptomatic based on the ACSM guidelines [31].
A letter describing the study components will be sent to the pro-
spective participant’s physician(s) for obtaining approval for exer-
cise testing and training, and for documenting the diagnosis of MS
based on Poser’s and/or McDonald’s criteria [34,35]. Once both
letters are returned to the research team, we will schedule the
baseline testing session for the provision of informed consent and
assessment of neurological function, walking, and physiological
function outcomes in the Exercise Neuroscience Research Labora-
tory. Participants will then be randomly assigned into either the FES
cycling or passive cycling condition using a random numbers
generator and concealed allocation. Participants will undertake the
respective programs over a 6-month period administered through
the Clinical Exercise Physiology Laboratory. Participants will un-
dergo the same assessment protocol as with baseline in the middle
and immediately after the 6-month period. Assessors will be blin-
ded to condition allocation. Participants will receive $50 for
completing the measurements on each of the three assessments.
2.7. Statistical analyses
Data analysis will be performed using IBM SPSS Statistics 22.0
(IBM Corp., Armonk, IL). We will initially examine the data for
outliers and non-normality. The effect of the intervention will be
examined using Condition  Time mixed model ANOVA. Condition
will be a between-subject factor and time will be a within-subjectIRB  
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Fig. 1. Flow diagram ofactor. Effect sizes associated with F-statistics will be expressed as
eta-squared (h2). Effect sizes based on a difference in mean scores
will be expressed as Cohen’s d. Bivariate correlations along with
multiple linear regression will be used for examining physiological
function variables as mediators of any FES cycling effect onmobility
[36].
3. Discussion
This RCTwill examine the efﬁcacy of 6 months of supervised FES
cycling for improving walking performance and physiological
function among persons with severe MS disability. The results of
this trial will provide important information for the design and
delivery of a future RCT by: (1) providing effect sizes that can be
included in a power analysis for optimal sample size estimation;
and (2) identifying cardiorespiratory ﬁtness, muscular strength,
and balance (i.e., physiological function) as mechanisms for the
beneﬁcial effects of FES cycling on walking performance. FES
cycling is a promising rehabilitation approach with the potential to
signiﬁcantly advance the management of progressive mobility
disability using exercise training in severe MS.
There are several novel aspects of this study. First, we are
examining exercise training among persons with severe MS
disability, a cohort that has historically received minimal research
attention regarding exercise training interventions [12]. TheAnalysis & 
Publication
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trials of FES cycling in persons with MS. To the best of our knowl-
edge, there are ﬁve published trials (4 non-RCTs, 1 case study) that
have examined FES cycling interventions in persons with MS
[20e22,37,38]. These studies have demonstrated initial safety and
feasibility, and preliminary beneﬁts for walking performance,
physical function, muscle strength and function, quality of life, and
spasticity. However, these trials have primarily involved small
samples, without a control condition, a limited number of training
sessions, and a have not examined the mechanisms responsible for
the beneﬁts of FES cycling. These limitations are signiﬁcant and
necessitate a well-designed trial of FES cycling in severe MS. Our
study will include a passive cycling condition that controls for so-
cial contact and leg movement by the ergometer. The intervention
will involve 24 weeks (3 sessions/week) of FES cycling or passive
cycling, and this is substantially longer than most previous in-
terventions. We will examine physiological function outcomes (i.e.,
aerobic capacity, muscular strength, and balance) as mechanisms
for the beneﬁcial effects of FES cycling on walking performance.
Overall, the design of this trial signiﬁcantly improves upon previous
research on FES cycling in MS and targets a speciﬁc patient group
that is in need of alternative strategies for managing MS disability.
This will provide important and much needed information on the
potential beneﬁts of FES cycling as an exercise rehabilitation tool.
If the proposed intervention is successful, the potential impact
for MS patients, clinicians, and therapists is considerable. Impor-
tantly, disease modifying agents have limited efﬁcacy in slowing
the eventual progression of walking disability in severe MS
[39e41]. Researchers have advocated for the development of
powerful approaches that limit the progression of mobility
disability [42e44], and rehabilitation has been recommended as
the only practical means to reduce disability and restore function in
MS [15]. Exercise-based rehabilitation using FES-cycling represents
one potential approach for restoring and managing walking
dysfunction in severe MS. If successful, FES cyling is an alternative
exercise training modality that could be integrated within current
rehabilitation regimens. There is tremendous long-term potential
for FES cycling within the home and community environment. FES
cycling is FDA approved for home-based therapy, the protocols can
be self-administer, and exercise training data can be accessed
remotely through the Internet for monitoring compliance and
tracking progression. This highlights the ability of FES cycling
programs to reach a substantial number of individuals with severe
MS, and would address many of the barriers to exercise participa-
tion (e.g., lack of transportation) faced by this patient group.
We will conduct the ﬁrst RCT of supervised FES cyling on out-
comes of walking performance and physiological function
compared to a credible control condition in patients with severeMS
disability. This study will provide critical pilot data to design and
implement a future large-scale RCT of FES cycling in persons with
severe MS, and therefore represents a ﬁrst step in this important
line of research. Considering the limited options for therapeutic
intervention, there is a critical need to explore innovative ap-
proaches for managing severe MS. FES cycling represents a novel
exercise rehabilitation approach for managing disability, restoring
function, and improving the lives of people with severe MS.Acknowledgements
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